---

Recent Advances in Rhinology - PG ENT Exam Topics (2024-2026)

---

1. BIOLOGICS FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSwNP)

Pathophysiology Background

FDA-Approved Biologics (as of 2025: three approved)

Dupilumab - Most Important (First approved for CRSwNP, 2019)

• SINUS-24 and SINUS-52 trials: Significant improvements in nasal polyp score (NPS), nasal congestion, Lund-Mackay CT score, SNOT-22, and olfaction (UPSIT)
• Reduces need for systemic corticosteroids and surgery
• Also approved for atopic dermatitis, asthma, and eosinophilic esophagitis - making it ideal for "united airway disease"
• Mechanism: blocks IL-4Ra subunit shared by IL-4 and IL-13 receptors

Omalizumab (anti-IgE)

• POLYP-1 and POLYP-2 trials: improved NPS and SNOT-22
• Useful in patients with comorbid allergic asthma and CRSwNP

Mepolizumab (anti-IL-5)

• SYNAPSE trial: reduced polyp burden and exacerbations
• Best for eosinophilic CRSwNP

Network Meta-analysis (2025) Key Finding

• Dupilumab shows superior efficacy over mepolizumab for NPS reduction [PMID: 39187717]
• All three are superior to placebo for polyp burden reduction [PMID: 39985317]

Exam Pearls

• First-line biologics only after: maximal medical therapy (intranasal corticosteroids + saline) has failed AND surgery has been considered
• Biologics also reduce revision ESS rates in tertiary centers (2026 data)
• Tezepelumab (anti-TSLP) is emerging as a fourth agent - targets epithelial-immune interface (TSLP is the "upstream" alarmin)
• Benralizumab (anti-IL-5Ra) - under trial for CRSwNP

---

2. UNIFIED AIRWAY CONCEPT / TYPE 2 ENDOTYPE

Key Concept for PG Exams

Epithelial Alarmin Theory

• TSLP, IL-25, IL-33 are "alarmins" released by damaged epithelium
• They activate ILC2s upstream of T2 inflammation
• This is why anti-TSLP (tezepelumab) works at the very top of the inflammatory cascade

Endotyping vs Phenotyping

• Phenotype: Clinical presentation (CRSwNP vs CRSsNP)
• Endotype: Underlying molecular mechanism (Type 2 vs non-Type 2)
• Type 2 CRS = elevated tissue/blood eosinophils, elevated IgE, periostin - these predict biologic response

---

3. ADVANCES IN FUNCTIONAL ENDOSCOPIC SINUS SURGERY (FESS)

Image-Guided Surgery (IGS) / Navigation

• Electromagnetic or optical tracking systems correlate pre-op CT with intraoperative anatomy in real time
• Indications: revision surgery, distorted anatomy, skull base/orbital wall extension, close proximity to optic nerve or carotid
• Not a substitute for surgical skill - landmark-based surgery remains the gold standard
• Reduces complications in difficult anatomy

Extended FESS / Mega-ANTROSTOMY

• Maximal ethmoidectomy + wide sphenoidotomy + large antrostomies
• Better for severe CRSwNP with diffuse polyposis
• Modified Lothrop (Draf III) procedure for frontal sinus: creates a common neoostium by removing the frontal sinus floor; used in revision cases and aspirin-exacerbated respiratory disease (AERD)
• Draf III with steroid irrigation shown to reduce biologic dependence in refractory CRSwNP (ARS 2025 data)

Frontal Sinus Surgery Advances

• Draf classification: I (removal of agger nasi), IIa/IIb (enlargement of natural ostium), III (modified Lothrop - bilateral drainage)
• White-light and 4K/3D endoscopes improving visualization

Mini-FESS vs Full FESS

• Ongoing debate: mini-FESS (OMU only) vs "full-house" FESS
• Evidence does not clearly favor one over the other - patient selection is key

Drug-Eluting Implants

• Steroid-eluting stents (e.g., PROPEL mometasone stent) placed intraoperatively
• FDA approved; releases mometasone over 30 days post-FESS
• Reduces need for oral steroids and surgical re-intervention
• Decreases polypoid edema and middle turbinate lateralization

---

4. BALLOON SINUPLASTY (BALLOON CATHETER DILATION)

Mechanism

• Sinus ostia dilated with an inflatable balloon catheter under endoscopic guidance (no tissue removal)
• Uses Seldinger technique with a guidewire into sinus

Evidence

• 80.5% patency at 6 months, 85.1% at 1 year, 91.6% at 2 years
• Small RCTs show non-inferiority to FESS
• Cadaveric study concern: true maxillary ostium may be missed; false ostium in posterior fontanelle may be created instead

Best Candidates

• Mild-to-moderate CRS without nasal polyps
• Frontal sinusitis (Draf type I equivalent)
• Office-based balloon sinuplasty is now increasing - 140% increase in office-based procedures in 2 years

Controversy

• Not suitable for CRSwNP (no polyp removal)
• High disposable cost (reusable balloons entering market)
• Larger robust RCTs still needed

---

5. OFFICE-BASED RHINOLOGY PROCEDURES

Current Office-Based Procedures

• Balloon sinuplasty (in-office)
• In-office polypectomy (using suction debriders)
• Coblation turbinoplasty - radiofrequency ablation of inferior turbinate
• Cryotherapy for allergic rhinitis - targets postganglionic parasympathetic nerves in the inferior turbinate (FDA-approved, Clarifix device)
• Intralesional steroid injection to polyps
• Office-based septoplasty (emerging)
• Vidian neurectomy via endoscopic approach (refractory vasomotor rhinitis)

Clarifix (Cryotherapy)

• Delivers -70°C to the posterior nasal nerve area
• FDA approved for chronic rhinitis
• Reduces rhinorrhea and congestion
• Exam point: targets postganglionic parasympathetic fibers

---

6. POST-COVID OLFACTORY DYSFUNCTION (PCOD)

Pathophysiology

• SARS-CoV-2 infects sustentacular cells (support cells) in olfactory epithelium via ACE2 receptors - NOT olfactory neurons directly
• Sustentacular cell damage leads to secondary olfactory neuron dysfunction
• Neuroinflammation, microglial activation, and axonal damage in the olfactory bulb occur in persistent cases

Classification

• Anosmia: Complete loss of smell
• Hyposmia: Reduced smell
• Parosmia: Distorted smell (often food smells as foul/burnt) - a sign of regeneration
• Phantosmia: Olfactory hallucination without stimulus

Treatment Advances

• Olfactory training (OT): Gold standard - sniffing 4 odors (rose, eucalyptus, lemon, clove) twice daily for 12+ weeks; promotes neuroplasticity
• Theophylline nasal drops: Phosphodiesterase inhibitor, increases cAMP in olfactory neurons
• Vitamin A nasal drops: Supports olfactory epithelium regeneration
• Intranasal steroids: Limited evidence for post-COVID OD
• PRP (Platelet-Rich Plasma) intranasal injection: Emerging - contains growth factors (PDGF, VEGF, TGF-b) to promote olfactory neuroregeneration
• Insulin nasal drops: Emerging (systematic review 2023) - insulin receptors present in olfactory epithelium [PMID: 37776014]
• Photobiomodulation (low-level laser): Systematic review 2025 shows promising results for post-COVID olfactory recovery [PMID: 40522371]
• Stellate ganglion block: Case reports/small trials - reduces neuroinflammation

Exam Pearl

• Parosmia is a positive sign - indicates olfactory nerve regeneration (even if distorted)
• SNOT-22 does NOT include olfaction - use UPSIT (University of Pennsylvania Smell Identification Test) or Sniffin' Sticks for objective measurement

---

7. ALLERGIC RHINITIS - RECENT ADVANCES

Precision Immunotherapy

• Subcutaneous Immunotherapy (SCIT) vs Sublingual Immunotherapy (SLIT):
  • Meta-analysis 2023 (children): SLIT has comparable efficacy with better safety profile [PMID: 38162647]
  • SCIT remains gold standard for systemic (multi-allergen) desensitization
  • SLIT tablets (grass, house dust mite) FDA/EMA approved

Biologics in AR

• Dupilumab also approved for AR with comorbid atopic dermatitis or asthma
• Combination of immunotherapy + biologics: Rational approach in severe cases [PMID: 40349962]

Biomarkers

• Nasal mucus proteomics: identifying AR endotypes
• Periostin, eotaxin-3 as T2 biomarkers

Omalizumab for Severe AR

• Used in patients with severe AR refractory to SCIT

---

8. ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD) / SAMTER'S TRIAD

Triad

Pathophysiology

• COX-1 inhibition → reduced PGE2 → excess cysteinyl leukotrienes (LTC4, LTD4, LTE4) via 5-LOX pathway
• Mast cell and eosinophil activation, platelet-leukocyte aggregates

Recent Advances

• Aspirin desensitization (Stevenson protocol): Gradual dose escalation under medical supervision → tolerance achieved; reduces polyp recurrence and improves olfaction
• Dupilumab for AERD: Highly effective - best evidence among all CRSwNP subtypes
• Leukotriene modifiers: Montelukast, zileuton (5-LOX inhibitor) as adjuncts
• Platelet-derived eicosanoids (TXA2) role now recognized

---

9. ALLERGIC FUNGAL RHINOSINUSITIS (AFRS) - RECENT UNDERSTANDING

Characteristics

• Type 2 (T2) immune response to ubiquitous fungi (Bipolaris, Curvularia, Aspergillus)
• Classic triad: eosinophilic mucin + fungal hyphae + immunocompetent host
• Weir & Bhattacharyya criteria / Bent & Kuhn criteria

New Insights

• T2 inflammation dominant (same as CRSwNP) - elevated IgE (total and fungal-specific), elevated eosinophils
• Dupilumab showing efficacy in AFRS as well
• Post-surgical relapse rate ~60-90% within 1 year without adjuvant therapy
• Immunotherapy against fungal antigens - reducing relapse

---

10. SINONASAL MICROBIOME

Key Concept

• Healthy sinus: Staphylococcus epidermidis, Corynebacterium dominant
• CRS: Dysbiosis - reduction of commensal bacteria, relative increase of S. aureus, P. aeruginosa, Haemophilus influenzae
• S. aureus biofilms and superantigens drive T2 inflammation in CRSwNP

Clinical Applications

• Biofilm-disrupting irrigation protocols (e.g., baby shampoo nasal rinse at 1%)
• Bacteriophage therapy: Experimental - targeting specific pathogens like P. aeruginosa in CRS
• Probiotic nasal sprays under investigation

---

11. ADVANCES IN IMAGING AND ENDOSCOPY

4K / 3D Endoscopy

• Superior depth perception and detail
• Useful for skull base and orbital surgery

MRI Rhinology

• T2-weighted MRI: excellent soft tissue differentiation
• Useful for AFRS (hypointense eosinophilic mucin on both T1 and T2)
• DWI (diffusion-weighted imaging): distinguish mucocele from cholesterol granuloma

AI in Sinus CT

• Artificial intelligence algorithms for automated Lund-Mackay scoring
• Predictive modeling for surgical outcomes

Sinonasal Outcomes Measurement

• SNOT-22 (SinoNasal Outcome Test-22): validated PROMs for CRS
• UPSIT for olfaction
• Nasal Cytology: brush biopsy for endotyping (eosinophil count)

---

12. EPISTAXIS - RECENT ADVANCES

Hereditary Hemorrhagic Telangiectasia (HHT) / Osler-Weber-Rendu Disease

• Intralesional sclerotherapy (polidocanol or sodium tetradecyl sulfate): more efficacious than laser alone for HHT-associated epistaxis; reduces breakthrough epistaxis and intraoperative blood loss (2026 data)
• Bevacizumab (anti-VEGF) intranasal spray: FDA-approved; reduces epistaxis frequency in HHT
• Tranexamic acid nasal spray: Antifibrinolytic; topical use for recurrent epistaxis

Management Algorithm

• Anterior bleeding: cautery (chemical with silver nitrate or electrocautery) > packing
• Posterior bleeding: endoscopic sphenopalatine artery ligation (ESPAL) or embolization
• ESPAL is now preferred over posterior nasal packing - lower morbidity, higher success rate

---

13. CYSTIC FIBROSIS AND RHINOLOGY

CFTR Modulators - Major Advance

• Elexacaftor/Tezacaftor/Ivacaftor (ETI / Trikafta): Triple CFTR modulator
• Improves mucociliary clearance, reduces sinusitis, improves olfaction in CF patients
• Pediatric study (ARS 2025): ETI significantly improves olfaction and sinonasal symptoms in CF children
• Exam point: ETI works for F508del mutation (most common CF mutation)

---

14. CEREBROSPINAL FLUID (CSF) RHINORRHEA - ADVANCES

Endoscopic Repair

• Endoscopic endonasal approach has replaced open craniotomy for most cases
• High-flow vs Low-flow leaks: CT cisternography + intrathecal fluorescein localization
• Nasoseptal flap (Hadad flap): Pedicled vascular flap (based on posterior nasal artery) - gold standard for reconstruction
• Multilayer repair: fat graft + fascia lata + nasoseptal flap + tissue glue
• Success rate >90% for primary repair endoscopically

Beta-2-Transferrin

• Most specific biochemical marker for CSF (>95% sensitivity, >99% specificity)
• Beta-trace protein (prostaglandin D synthase) - equally specific, faster result

---

15. NASAL HYPERREACTIVITY / VASOMOTOR RHINITIS

Non-Allergic Rhinitis With Eosinophilia Syndrome (NARES)

• Responds to intranasal steroids
• T2 biomarkers elevated despite negative allergy testing

Vidian Neurectomy

• Endoscopic approach targeting the Vidian nerve (nerve of the pterygoid canal)
• Reduces parasympathetic rhinorrhea in refractory non-allergic rhinitis
• Less morbidity vs open approach

Cryotherapy (ClariFix)

• Posterior nasal nerve cryoablation at -70°C
• FDA approved 2017
• 3-month durability, minimal adverse effects

---

16. INVERTED PAPILLOMA - RECENT ADVANCES

Endoscopic Resection

• Endoscopic en bloc or drill-through resection now preferred over lateral rhinotomy
• Recurrence rate: 5-15% with endoscopic approach (same as open)
• HPV 6 and 11 associated; HPV 16 and 18 associated with malignant transformation
• Staging: Krouse staging system (T1-T4)
• Malignant transformation risk: 5-15% to squamous cell carcinoma

New Insight

• EBV and HPV integration studied as biomarkers for malignancy risk
• MRI (T2 and convoluted cerebriform pattern) is pathognomonic

---

17. RHINOPLASTY / SEPTOPLASTY ADVANCES

Piezoelectric Surgery (Piezosurgery)

• Ultrasonic bone cutting - precise, spares soft tissue
• Used for septoplasty, osteotomy in rhinoplasty
• Advantages: less bleeding, less periosteal stripping, faster healing

Spreader Grafts and Autologous Cartilage

• Improved internal nasal valve repair using spreader grafts

Computer-Aided Rhinoplasty Planning

• 3D imaging and simulation software (e.g., Vectra) for patient education and surgical planning

---

SUMMARY TABLE FOR EXAM REVISION

---

Recent Literature (High-Yield References)

• Dupilumab vs Mepolizumab network meta-analysis: [PMID 39187717] (2025)
• Real-world biologics efficacy meta-analysis: [PMID 39985317] (2025)
• SLIT vs SCIT in children: [PMID 38162647] (2024)
• Photobiomodulation for post-COVID anosmia: [PMID 40522371] (2025)
• Biologics for pediatric CRS: [PMID 38488239] (2024)